Restricted accessResearch articleFirst published online 2019-07
Therapeutic Delivery of miR-143 Targeting Tumor Metabolism in Poorly Differentiated Thyroid Cancer Xenografts and Efficacy Evaluation Using 18 F-FDG MicroPET-CT
Poorly differentiated thyroid carcinoma cells tend to be more aggressive and show enhanced glucose uptake which could be exploited for anti-cancer strategy. Previously, we identified hexokinase 2 (HK2) as a direct target of miR-143. In our current study, the effects of miR-143 on glucose metabolism and tumor biological behavior were investigated in FTC-133 cells which is a poorly differentiated thyroid carcinoma (PDTC). Additionally, tumor-bearing mice xenografts of PDTC were constructed, with encapsulated miR-143 agomir being administered intravenously. 18F-FDG microPET-CT scanning was used for the evaluation of therapeutic efficacy. The tumor-restrained effect of miR-143 was demonstrated in PDTC. Furthermore, microPET/CT imaging exhibited a reduction of 18F-FDG uptake in tumors, corresponding to the downregulated expression of HK2 in tissues. In summary, our results suggest that miR-143 can be an alternative treatment for PDTC and the specific assessment of therapeutic response to miR-143 can be achieved by 18F-FDG microPET/CT in advanced thyroid carcinoma xenografts.
Get full access to this article
View all access options for this article.
References
1.
KitaharaCM, SosaJA. The changing incidence of thyroid cancer. Nat Rev Endocrinol, 2016; 12:646–653.
2.
GerberTS, SchadA, HartmannN, et al.Targeted next-generation sequencing of cancer genes in poorly differentiated thyroid cancer. Endocr Connect, 2018; 7:47–55.
3.
LandaI, IbrahimpasicT, BoucaiL, et al.Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest, 2016; 126:1052–1066.
4.
BroseMS, NuttingCM, JarzabB, et al.Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet, 2014; 384:319–328.
5.
SchlumbergerM, TaharaM, WirthLJ, et al.Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. New Engl J Med, 2015; 372:621–630.
6.
HanahanD, WeinbergRA. Hallmarks of cancer: the next generation. Cell, 2011; 144:646–674.
7.
FeineU, LietzenmayerR, HankeJP, et al.Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med, 1996; 37:1468–1472.
8.
GrabellusF, NagarajahJ, BockischA, et al.Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma. Clin Nucl Med, 2012; 37:121–127.
9.
VaismanF, CarvalhoDP, VaismanM. A new appraisal of iodine refractory thyroid cancer. Endocr Relat Cancer, 2015; 22:R301-R310.
10.
WangH, WangL, ZhangY, et al.Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth. Cancer Cell Int, 2016; 16:9.
11.
VartanianA, AgnihotriS, WilsonMR, et al.Targeting hexokinase 2 enhances response to radio-chemotherapy in glioblastoma. Oncotarget, 2016; 7:69518–69535.
12.
AmbrosV.The functions of animal microRNAs. Nature, 2004; 431:350–355.
13.
ZhangLF, JiangS, LiuMF. MicroRNA regulation and analytical methods in cancer cell metabolism. Cell Mol Life Sci, 2017; 74:2929–2941.
14.
KarimiL, MansooriB, ShanebandiD, et al.Function of microRNA-143 in different signal pathways in cancer: New insights into cancer therapy. Biomed Pharmacother, 2017; 91:121–131.
15.
HartmannJU, Brauer-HartmannD, KardosovaM, et al.MicroRNA-143 targets ERK5 in granulopoiesis and predicts outcome of patients with acute myeloid leukemia. Cell Death Dis, 2018; 9:814.
16.
JahanbaniI, Al-AbdallahA, AliRH, et al.Discriminatory miRNAs for the management of papillary thyroid carcinoma and noninvasive follicular thyroid neoplasms with papillary-like nuclear features. Thyroid, 2018.
17.
JiangS, ZhangLF, ZhangHW, et al.A novel miR-155/miR-143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells. EMBO J, 2012; 31:1985–1998.
18.
MassartC, DenaisA, GibassierJ. Effect of all-trans retinoic acid and sodium butyrate in vitro and in vivo on thyroid carcinoma xenografts. Anticancer Drugs, 2006; 17:559–563.
19.
ZhangM, GuoR, XuH, et al.Retinoic acid and tributyrin induce in-vitro radioiodine uptake and inhibition of cell proliferation in a poorly differentiated follicular thyroid carcinoma. Nucl Med Commun, 2011; 32:605–610.
20.
ZhangLF, LouJT, LuMH, et al.Suppression of miR-199a maturation by HuR is crucial for hypoxia-induced glycolytic switch in hepatocellular carcinoma. EMBO J, 2015; 34:2671–2685.
21.
WigginsJF, RuffinoL, KelnarK, et al.Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res, 2010; 70:5923–5930.
22.
HayN.Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy?. Nat Rev Cancer, 2016; 16:635–649.
23.
BaigMH, AdilM, KhanR, et al.Enzyme targeting strategies for prevention and treatment of cancer: Implications for cancer therapy. Semin Cancer Biol, 2017.
24.
NahmJH, KimHM, KooJS. Glycolysis-related protein expression in thyroid cancer. Tumour Biol, 2017; 39:1010428317695922.
25.
ChangL, ZhangD, ShiH, et al.MiR-143 inhibits endometrial cancer cell proliferation and metastasis by targeting MAPK1. Oncotarget, 2017; 8:84384–84395.
26.
LeiC, DuF, SunL, et al.miR-143 and miR-145 inhibit gastric cancer cell migration and metastasis by suppressing MYO6. Cell Death Dis, 2017; 8:e3101.
27.
GuopingM, RanL, YanruQ.miR-143 inhibits cell proliferation of gastric cancer cells through targeting GATA6. Oncol Res, 2018.
28.
WangJH, WangXW, QuD, et al.Upregulation of microRNA-143 reverses drug resistance in human breast cancer cells via inhibition of cytokine-induced apoptosis inhibitor 1. Oncol Lett, 2017; 13:4695–4700.
29.
SunX, DaiG, YuL, et al.miR-143–3p inhibits the proliferation, migration and invasion in osteosarcoma by targeting FOSL2. Sci Rep, 2018; 8:606.
30.
LiS, FangXD, WangXY, et al.Fos-like antigen 2 (FOSL2) promotes metastasis in colon cancer. Exp Cell Res, 2018; 373:57–61.
31.
WangJ, LiQ, WangC, et al.Knock-down of CIAPIN1 sensitizes K562 chronic myeloid leukemia cells to Imatinib by regulation of cell cycle and apoptosis-associated members via NF-kappaB and ERK5 signaling pathway. Biochem Pharmacol, 2016; 99:132–145.
ZhouP, ChenWG, LiXW. MicroRNA-143 acts as a tumor suppressor by targeting hexokinase 2 in human prostate cancer. Am J Cancer Res, 2015; 5:2056–2063.
34.
YoshinoH, EnokidaH, ItesakoT, et al.Tumor-suppressive microRNA-143/145 cluster targets hexokinase-2 in renal cell carcinoma. Cancer Sci, 2013; 104:1567–1574.
35.
MiaoY, ZhangLF, GuoR, et al.(18)F-FDG PET/CT for monitoring the response of breast cancer to miR-143-based therapeutics by targeting tumor glycolysis. Mol Ther Nucleic Acids, 2016; 5:e357.
36.
HaugenBR, AlexanderEK, BibleKC, et al.2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 2016; 26:1–133.
37.
LeboulleuxS, SchroederPR, SchlumbergerM, et al.The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers. Nat Clin Pract Endocrinol Metab, 2007; 3:112–121.
38.
LiuM, ChengL, JinY, et al.Predicting (131)I-avidity of metastases from differentiated thyroid cancer using (18)F-FDG PET/CT in postoperative patients with elevated thyroglobulin. Sci Rep, 2018; 8:4352.
39.
AlvarezJV, BelkaGK, PanTC, et al.Oncogene pathway activation in mammary tumors dictates FDG-PET uptake. Cancer Res, 2014; 74:7583–7598.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
